HIV/AIDS News

BOSTON — An increased risk for language impairment was observed among HIV-exposed but uninfected children aged 3 to 5 years; however, no overall risk was found to be associated with ART, according to data presented at CROI 2016.

The FDA recently approved Odefsey, a tenofovir alafenamide-based regimen, for the treatment of HIV-1 infection, according to a press release from the drug’s manufacturer.

BOSTON — Switching from a program that only provided ART treatment to eligible pregnant women to a program that provided universal ART helped increase treatment initiation and antenatal retention in Swaziland, according to data presented at CROI 2016.

BOSTON — Elaine J. Abrams, MD, professor of pediatrics and epidemiology at Columbia University Medical Center, discusses highlights from a session on pediatric HIV infection presented at the 2016 Conference on Retroviruses and Opportunistic Infections.

BOSTON — HIV exposure and infection accounted for more than half of the deaths among children aged 24 months in Botswana, a country with widespread availability of maternal and infant ART, according to data presented at CROI 2016.

BOSTON — Co-trimoxazole, used to reduce mortality in HIV-infected infants, did not improve survival rates for infants exposed to HIV in utero but uninfected with the virus, according to data presented at CROI 2016.

BOSTON — Viread used by women during pregnancy did not negatively affect bone mineral content in their infants when compared with the use of zidovudine, according to data presented at CROI 2016.

In a recent hearing, members of the House Committee on Oversight and Government Reform questioned representatives from Turing Pharmaceuticals and Valeant Pharmaceuticals on the recent market price increases of various off-patent medications.

Targeted, multilevel strategies are needed to reduce risk behaviors among young men who have sex with men living with HIV, particularly among those with a detectable viral load, according to a study published in JAMA Pediatrics.

An omnibus bill that included increased funding to reduce antibiotic resistance and support syringe service programs was passed on Friday by a 65-33 vote in the Senate and a 316-113 vote in the House.